Figure 2 from CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy

In xenograft tumors that show strong response to SAIL66 administration, the expression of CLDN6 is significantly reduced under vivo growth conditions. A, Tumor growth inhibition by SAIL66 (1 mg/kg) in huNOG mice bearing NIH:OVCAR-3 and OV-90 xenografts compared with vehicle-treated control group (n = 8 per group). B, Western blot analysis of CLDN6 protein levels in NIH:OVCAR-3 and OV-90 cultured in vitro and xenograft tumors established in mice (in vivo). C, qPCR analysis of CLDN6 gene expression in NIH:OVCAR-3 and OV-90 cultured in vitro and tumors established in mice (in vivo). Quantitative data are presented as the mean ± SD. Two-tailed Student t test. ***, P < 0.001; ****, P < 0.0001.